Why
so many vaccines in race
The WHO lists 165 outbreaks of
coronavirus vaccines. The reasons for the high number range from the need for
many alternatives to new research opportunities and funding
According to a recent list by
the World Health Organization (WHO), at least 165 vaccines to study coronavirus
were developed worldwide. The actual number can be three times the number
entered in the WHO. Those on the list all fall into at least one phase of
pre-treatment trials. Some are in the final stages of human testing, perhaps
just a few months away from hitting the market (a Russian vaccine promises to
be ready in a few weeks), while many others are just getting into animal tests
and maybe a few years from then ready.
But
why are so many goals being developed all at once?
Here are some answers: The
success rate remains low The goal development is complex, time-consuming,
resource-intensive, and the chances of success are very low. Of the 100 voters
considered in child labor centers, approximately 20 make it to the
pre-diagnosis stage. This means that about 80% of potential candidates are not
considered animal-friendly. Thereafter, not more than one-fifth of the total
expenditure is approved for human testing and in this case, not more than one
or two have the potential to be approved for public use.
According to the current
situation, 165 people selected for the WHO list all meet at least a pre-illness
test phase and at least 23 of them are in a human trial. Not all of these will
succeed. While we are all given to understand that it was only a matter of a
few months before other top leaders, such as the one formed by Oxford
University, were on the market, the reality is very different. Even those in the
final stages of human trials, with encouraging results from previous stages,
are not guaranteed to succeed.
The Phase III trials, in which
a vaccine is tested to protect against infection in humans in real-life
situations (other than laboratory conditions), are a solid part of the trial.
Countries with strong regulatory systems are likely to be able to lower their
bar due to the current emergency. The effectiveness of vaccination for
phase-III trials is important.
Finally, we do not anticipate
the emergence of hundreds of coronavirus vaccines. Even if only five or six are
successful, that can be considered a good level of success. More vaccines are
needed If you think everyone would want to get their hands on a vaccine as soon
as possible, a single vaccine is unlikely to meet the global demand. There are
already indications that some countries may be flooded with new vaccines,
leaving some waiting to be available in the future.
The US, for example, has
entered into multi-billion dollar agreements with many leading opponents, and
booked hundreds of millions of dollars ahead of time. This may be restrictions
on access to other countries, especially in a developing and poor country. That
is why several countries have begun their efforts to develop a vaccine.
Countries such as Egypt,
Thailand, Nigeria, Argentina, which are not known for vaccine research, are all
in the race. Even if they arrive too late, if they succeed, they will have
control over production and shipping. "Having a diversity of nominees reduces
the chances of exploitation by sectors within the country or internationally
... against each other because there are many injectable injections with
different distribution channels.
There is another reason why
many vaccines are so effective. There is no guarantee that the first one will
be the most efficient. These vaccines are established quickly, and there is a
chance that those who arrive late will not be able to learn from the
experiences of the first ones, and make the transition to success. New technologies
are being tested As they flee.